Skip to content

ISB, SSNB, and PENG Block for Arthroscopic Shoulder Surgery

Comparative Study Between Interscalene Nerve Block, Anterior Suprascapular Nerve Block, and Pericapsular Nerve Group Block for Arthroscopic Shoulder Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05739201
Enrollment
90
Registered
2023-02-22
Start date
2023-02-20
Completion date
2023-12-20
Last updated
2023-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interscalene Nerve Block, Anterior Suprascapular Nerve Block, Arthroscopic Shoulder Surgery

Brief summary

This study is designed to investigate the post-operative analgesic effect of interscalene nerve block or anterior suprascapular nerve block compared to pericapsular nerve group block in patient undergoing elective arthroscopic shoulder surgery.

Detailed description

Shoulder arthroscopy is a common outpatient operation with an increasing number of indications and complexity. Early postoperative pain immediately following shoulder surgery is a major concern and cause of distress for patients and orthopedic surgeons. Adequate pain control is vital for all aspects of the patient's recovery. Nowadays, several ultrasound -guided regional anesthesia methods are used for postoperative analgesia. Regional techniques such as interscalene and supraclavicular blocks are usually preferred for shoulder analgesia. Interscalene brachial plexus block (ISB) is the gold standard technique in this area. Suprascapular nerve block (SSB) has been proposed as an alternative to the ISB in providing analgesia for shoulder surgeries as it has a lower likelihood of causing phrenic nerve blockade. The pericapsular nerve group (PENG) block has been suggested to be safely applied for analgesia and can be part of surgical anesthesia, but alone is not sufficient for anesthesia in shoulder surgery. The block of this area did not cause motor block or pulmonary complications, nor result in muscle laxity, blocking only the shoulder and the upper third of the humerus.

Interventions

Patients will receive interscalene nerve block, in which the patient will be in supine position with the head turned to the contralateral side using an ultrasound scan to identify the C5 and C6 nerve roots between the scalene muscles.15 ml of 0.25% Bupivacaine will be deposited between the C5 and C6 nerve roots, within the interscalene groove using a 22 gauge-regional block needle.

PROCEDUREanterior suprascapular nerve block

Patients will receive anterior suprascapular nerve block, in which the patient will be in supine position with the head turned to the contralateral side, using an ultrasound the nerve will be traced as it diverges from the brachial plexus to lie under the omohyoid muscle in the supraclavicular fossa. 15 ml of 0.25% Bupivacaine will be deposited lateral to the suprascapular nerve, underneath the omohyoid muscle using a 22 gauge-regional block needle.

Patients will receive PENG block, in which the patient will be in supine position and the patient's arm will be placed in external rotation and abducted at 45 degrees, using an ultrasound the humeral head, the tendon of the subscapularis muscle and the deltoid muscle over it will be defined, 15 ml of 0.25% Bupivacaine will be placed between the deltoid muscle and subscapularis tendon using a 22 gauge-regional block needle.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients. * ASA class I and II and scheduled for elective shoulder arthroscopy.

Exclusion criteria

* Patient who refuses the regional anesthesia technique. * History of allergy to local anesthetics. * Local infection at the site of the block. * History of Pre-existing major organ dysfunction such as hepatic and renal failure. * History of pre-existing lung disease (COPD, uncontrolled asthma). * Preexisting upper extremity neurological abnormality or neuropathy. * Difficulties in comprehending (NRS). * Chronic opioid users (opioid intake more than 3 months).

Design outcomes

Primary

MeasureTime frameDescription
the total opioid consumption.24-hour postoperativelyPostoperative analgesia will be assessed by total opioid consumption and time till administration of first rescue analgesia will be recorded.

Countries

Egypt

Contacts

Primary ContactShrouk M Elsawaf, Master
Shroukms95@gmail.com+201091533902

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026